CENTER FOR IMMUNIZATION RESEARCH

# MILESTONES



First human trials of a preventive human papillomavirus cervical cancer vaccine (HPV 16). This virus-like particle (VLP) vaccine was the progenitor of the HPV vaccine (Gardasil) recently licensed by the FDA, & of a second vaccine (Cervarix).

• 1997-2001

• 1998-2003

## 1998-2003 •····

1998-2003 •---

1999-2003 •

**VaxGen, Inc.** Lead clinical trial site in first phase III HIV vaccine trial.

# NIH/NIAID

Lead clinical trial site for first human studies of live attenuated recombinant RSV vaccines.

# Avant/Microscience

Leading single dose, oral cholera (Peru-15) & typhoid vaccines (MICRO-TY/ZH9) shown to be safe & immunogenic in early Phase I/II trials performed in Baltimore & Vermont (typhoid only).

#### SBL Vaccines

Established efficacy of whole cell ETEC vaccine in field trials in Guatemala & Mexico.

# • 1998-2002

# Salix

Multicenter clinical trials that led to licensure of Rifamixin for treatment of traveler's diarrhea.

**NIH/NIAID** First human trial of a recombinant dengue virus vaccine; additional trials are ongoing. 6

• 1999-2006

2000-2002 •

## Intellivax

First human trial of intranasal Shigella vaccine demonstrated short-term protection against Shigella flexneri in an experimental challenge model.

#### NIH/DAIDS/HVTN & AlphaVax, Inc.

Lead clinical trial site for 1st human study of HIV vaccine using Venezuelan Equine Encephalitis vector.

### 2000-2005

2000-2005

# Acambis/IOMAI

Challenge studies evaluating ETEC vaccines demonstrated that anti-CS3 serum IgA titer is a marker for protection against strains sharing this colonization factor.

## Merck & Co.

Lead site for the first human testing of a live-attenuated adenovirus vectored HIV vaccine.

• 2001-2006


# NIH/NIAID

First human trial of malaria transmission blocking vaccine.

2002 •

CENTER FOR IMMUNIZATION RESEARCH

# MILESTONES



2006-2007 •

#### IOMAI

Phase II field study finds an ETEC vaccine delivered transcutaneously by arm patch protects travelers to Guatemala and Mexico.

# PATH/EVI

Developed and validated low-inoculum ETEC challenge model in human volunteers that enabled 2 log reduction in challenge strain while maintainging consistently high attack rates.

• 2009

# **CSL Limited**

2009 •

Principal Investigators and lead site in a large multicenter trial of a pandemic H1N1 influenza vaccine.

#### Norovirus Vaccine Against Experimental Human Norwalk Virus Illness

This norovirus VLP vaccine provides protection against illness and infection after challenge with a homologous virus.


• 2011

2012 •-----

# ACIP Appointment

Dr. Ruth Karron was appointed to the Advisory Committee on Immunization Practices. CENTER FOR IMMUNIZATION RESEARCH

MILESTONES



#### **MILESTONE NO. 12**

Lorem ipsum Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam.